Virtual Conference

March 26, 2022

Needs Statement

This symposium will bring together recognized national and international speakers to address recent advances in diagnosis of myelodysplastic syndrome (MDS) and measurable residual disease [MRD] directed acute myelogenousleukemia (AML) therapy. During our symposium, we will emphasize the need for physicians to combine up-to-date knowledge and technology to efficiently identify “actionable targets” for treatment of AML and MDS patients. Additionally, we expect to gain insight into promising scientific data that would inform therapy efficacy based on AML MRD evaluation. The symposium will provide important novel development in MDS and AML pathogenesis leading to unique opportunity for clinical trial design ideas.

Target Audience

Hematologists, primary care physicians, nurses, nurse practitioners, physician assistants, medical trainees and students

Learning Objectives

At the conclusion of the conference, participants should be able to:

• Integrate complex acute myelogenous leukemia (AML) genomic landscape into therapeutic and diagnostic algorithms 
• Describe the role of monoclonal antibodies for treatment of myelodysplasia
• Discuss the current role of targeted therapy in the treatment of acute myelogenous leukemia
• Summarize current epigenetic principles that explain leukemia initiation 

Educational Methods

Lecture and Panel Discussion

Activity Evaluation

Evaluation by questionnaire will address program content, presentation, and possible bias.